Document:

<PAGE>

                                                                     Exhibit 4.1

                       ==================================

                              AMENDED AND RESTATED

                             STOCKHOLDERS AGREEMENT

                        ENDO PHARMACEUTICALS HOLDINGS INC

                            Dated as of July 7, 2003

                       ==================================

<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                               Page
                                                                                                               ----
<S>                                                                                                            <C>
ARTICLE I
RESTRICTIONS ON TRANSFER OF STOCK.......................................................................         2
         1.1      General Restriction on Transfer by Management Stockholders............................         2
         1.2      Permitted Transferees.................................................................         3

ARTICLE II
PURCHASES BY ENDO LLC...................................................................................         4
         2.1      Right to Purchase Shares from Management Stockholders.................................         4
         2.2      Notice................................................................................         5
         2.3      Payment...............................................................................         5
         2.4      Postponement, etc.....................................................................         7

ARTICLE III
PURCHASE PRICE..........................................................................................         7
         3.1      Fair Market Value.....................................................................         7
         3.2      Carrying Value........................................................................         7
         3.3      Certain Defined Terms.................................................................         8

ARTICLE IV
PROHIBITION ON PURCHASES................................................................................        10
         4.1      Prohibited Purchases..................................................................        10

ARTICLE V
SALES TO THIRD PARTIES..................................................................................        12
         5.1      General...............................................................................        12
         5.2      Agreements to Be Bound................................................................        12
         5.3      Involuntary Transfers.................................................................        12
         5.4      Tag- and Drag-Along Rights............................................................        13

ARTICLE VI
REGISTRATION RIGHTS.....................................................................................        16
         6.1      Incidental Registration...............................................................        16
         6.2      Expenses..............................................................................        18
         6.3      Holdback and Other Agreements.........................................................        18
         6.4      Indemnification.......................................................................        19
</TABLE>

                                       i

<PAGE>

<TABLE>
<S>                                                                                                            <C>
ARTICLE VII
CHARTER DOCUMENTS.......................................................................................        20
         7.1      Charter Documents.....................................................................        20

ARTICLE VIII
TERMINATION.............................................................................................        20
         8.1      Sale of the Company...................................................................        20
         8.2      Cessation of Ownership of Stock.......................................................        21
         8.3      Other Termination Events..............................................................        21

ARTICLE IX
MISCELLANEOUS PROVISIONS................................................................................        21
         9.1      Stock Certificate Legend..............................................................        21
         9.2      Option Plans..........................................................................        22
         9.3      New Management Stockholders...........................................................        22
         9.4      No Other Arrangements or Agreements...................................................        22
         9.5      Amendment and Modification............................................................        23
         9.6      Assignment............................................................................        23
         9.7      Recapitalizations, Exchanges, etc. Affecting the Common Stock.........................        24
         9.8      Transfer of Common Stock..............................................................        24
         9.9      Further Assurances....................................................................        25
         9.10     Governing Law.........................................................................        25
         9.11     Invalidity of Provision...............................................................        25
         9.12     Notices...............................................................................        25
         9.13     Headings; Execution in Counterparts...................................................        26
         9.14     Entire Agreement; Effect on Certain Other Agreements..................................        27
         9.15     Injunctive Relief.....................................................................        27
         9.16     Attorneys' Fees.......................................................................        27
</TABLE>

                                       ii

<PAGE>

                   AMENDED AND RESTATED STOCKHOLDERS AGREEMENT

                  AMENDED AND RESTATED STOCKHOLDERS AGREEMENT, dated as of July
7, 2003 (this "Agreement"), by and among Endo Pharmaceuticals Holdings Inc., a
Delaware corporation (the "Company"), Kelso Investment Associates V, L.P., a
Delaware limited partnership (together with Kelso Equity Partners V, L.P., a
Delaware limited partnership, ("Kelso"), Endo Pharma LLC, a Delaware limited
liability company (together with its designee, "Endo LLC"), Carol A. Ammon,
Jeffrey R. Black and Mariann T. MacDonald (collectively, together with their
Permitted Transferees, the "Initial Management Stockholders"), David A.H. Lee
and the Carol A. Ammon Trustee, Revocable Trust U/A, Dated 6/13/97 as Permitted
Transferee of Carol A. Ammon (the Initial Management Stockholders, together with
David A.H. Lee and any other persons who become parties to this Agreement
pursuant to Sections 10.2 and 10.3 of this Agreement and each of their
respective Permitted Transferees, the "Management Stockholders").

                  WHEREAS, the Company, Kelso and the Management Stockholders
are parties to that certain Amended and Restated Stockholders Agreement, dated
as of July 14, 2000 (the "2000 Stockholders Agreement");

                  WHEREAS, the Company entered into an agreement and plan of
merger, dated as of November 26, 1999 (as may be amended and restated from time
to time, the "Merger Agreement"), by and among the Company, Endo Inc. and Algos
Pharmaceutical Corporation ("Algos") whereby Algos merged with and into Endo
Inc., a wholly owned subsidiary of the Company (the "Merger");

                  WHEREAS, the Company and Endo LLC have granted, and may grant
additional, options to purchase shares of common stock, par value $.01 per
share, of the Company (the "Common Stock") to the current Management
Stockholders and certain employees of the Company and its subsidiaries pursuant
to the Endo 1997 Employee Stock Option Plan, the Endo Pharma Amended and
Restated 1997 Employee Stock Option Plan, the Endo Pharma Amended and Restated
1997 Executive Stock Option Plan, the Endo Pharma 2000 Supplemental Employee
Stock Option Plan and the Endo Pharma 2000 Supplemental Executive Stock Option
Plan (collectively, and together with any similar such plan the Company may in
the future adopt, the "Option Plans") and, upon exercise of the options such
shares of Common Stock will be subject to this Agreement and to the extent such
employees are not already parties to this Agreement, such employees will become
parties to this Agreement pursuant to Section 10.3 hereof;

<PAGE>

                  WHEREAS, the Company may offer additional shares of Common
Stock after the date of this Agreement to employees of the Company and its
subsidiaries and such shares of Common Stock will be subject to this Agreement
and to the extent such employees are not already parties to this Agreement, such
employees will become parties to this Agreement pursuant to Section 10.3 hereof;
and

                  WHEREAS, the Company has filed a registration statement under
the Securities Act of 1933 (the "Act"), in connection with a public offering of
its common stock in which certain of the Management Stockholders may elect to
participate as selling stockholders;

                  WHEREAS, the Parties desire to amend the 2000 Stockholders
Agreement pursuant to Section 9.5 thereof, to clarify the scope of certain
rights granted thereunder in connection with Endo Pharma LLC's sales of the
Company's common stock; and

                  WHEREAS, the Company, Endo LLC and the Management Stockholders
believe it to be in their respective best interests and in the best interests of
the Company that they enter into this Agreement providing for certain rights and
restrictions with respect to the shares of Common Stock owned by the Management
Stockholders or their Permitted Transferees.

                  NOW, THEREFORE, in consideration of the mutual covenants and
obligations set forth in this Agreement, the parties hereto agree that the 2000
Stockholders Agreement is hereby amended and restated in its entirety and agree
as follows:

                                    ARTICLE I

                        RESTRICTIONS ON TRANSFER OF STOCK

                  1.1      General Restriction on Transfer by Management
Stockholders. No shares of Common Stock owned by any Management Stockholder or
any interest therein may, directly or indirectly, be sold, assigned, transferred
or otherwise disposed of or transferred by such Management Stockholder
(collectively, "Transferred" and any such transaction, a "Transfer"), except for
(i) Transfers to a transferee pursuant to Section 1.2 hereof (a "Permitted
Transferee"), (ii) Transfers of shares of Common Stock to the Company, Kelso,
Endo LLC or Management Stockholders, including pursuant to Article II or III
hereof, or (iii) Transfers of shares of Common Stock pursuant to, or as
otherwise permitted under, Article VI hereof; provided that

                                       2

<PAGE>

in the event the employment of a Management Stockholder with the Company or any
of its Subsidiaries is terminated for any reason, such Management Stockholder
may pledge, hypothecate, mortgage or encumber his or her shares of Common Stock;
provided further that the terms of any such pledge, hypothecation, mortgage or
encumbrance shall be approved by Endo LLC in its discretion taking into account
the financial situation of Endo LLC at the time.

                  1.2      Permitted Transferees.

                  (a)      Subject to paragraph (b) of this Section 1.2, any
Management Stockholder may Transfer any shares of Common Stock or any interest
therein or his or her rights to subscribe for the same, if any, (i) with the
prior written consent of Endo LLC's Board of Managers (the "LLC Board"), which
consent shall not be unreasonably withheld (provided that reasonable grounds to
withhold consent shall include, but not be limited to, the risk of subjecting
the Company to registration or reporting requirements under federal securities
laws), to a trust or corporation the beneficiaries or stockholders of which are
such Management Stockholder, as the case may be, his or her spouse, parents, any
other family members, (ii) in case of his or her death, by will or by the laws
of intestate succession to executors, administrators, testamentary trustees,
legatees or beneficiaries, or (iii) with the prior written consent of the LLC
Board, to any transferee, including, without limitation, to one or more
Management Stockholders or to any employee who is, in the opinion of the LLC
Board, a current member of management of the Company or any of its subsidiaries,
if any. In addition to the foregoing, any transferee of a Management Stockholder
described above may Transfer shares of Common Stock back to such Stockholder or
to another Permitted Transferee of such Stockholder.

                  (b)      Any Transfer of shares of Common Stock made pursuant
to paragraph (a) of this Section 1.2 to a Permitted Transferee shall be
permitted and shall be effective only if such Permitted Transferee shall agree
in writing to be bound by the terms and conditions of this Agreement pursuant to
an instrument of assumption reasonably satisfactory in form and substance to
Endo LLC.

                  (c)      An "affiliate" of, or a person "affiliated" with, a
specified person, is a person that directly or indirectly through one or more
intermediaries, controls, or is controlled by, or is under common control with,
the person specified (in the case of Kelso, including, without limitation, any
partner of such entity or any director or officer of Kelso & Company, any
individual retirement account of any such partner, director or officer, any
family member of any such partner, director or

                                       3

<PAGE>

officer, or any trust or family partnership for the benefit of any such partner,
director or officer or family member thereof).

                                   ARTICLE II

                              PURCHASES BY ENDO LLC

                  2.1      Right to Purchase Shares from Management
                           Stockholders.

                  (a)      Subject to all provisions of this Article III and
Article V hereof, Endo LLC shall have the right to purchase from a Management
Stockholder, and such Management Stockholder shall have the obligation to sell
to Endo LLC, all, but not less than all, of the shares of Common Stock owned by
such Management Stockholder:

                           (i)      at the fair market value of such shares, as
         determined pursuant to Section 4.1 hereof ("Fair Market Value"), if
         such Management Stockholder's employment with the Company or any of its
         subsidiaries is terminated as a result of (v) the termination by the
         Company or one of its subsidiaries of such employment without Cause,
         (w) the resignation of such Management Stockholder for Good Reason, (x)
         the resignation of such Management Stockholder without Good Reason, (y)
         the retirement of such Management Stockholder upon or after reaching
         the age of 65 or, if different, the Company's normal retirement age
         ("Retirement"), or (z) the death or Disability (as defined in Section
         4.3 hereof) of such Management Stockholder; and

                           (ii)     at the lesser of the Fair Market Value and
         the Carrying Value (as defined in Section 4.2 hereof) of such shares,
         if such Management Stockholder's employment with the Company or any of
         its subsidiaries is terminated by the Company or one of its
         subsidiaries with Cause.

                  (b)      In the event that Endo LLC does not exercise such
right to purchase the shares of Common Stock from a Management Stockholder by
giving notice within the 30-day period referred to in Section 3.2 hereof, Kelso,
or a party designated by Kelso, shall have the right to purchase, at its option,
the shares of Common Stock referred to in Section 3.1(a) hereof from such
Management Stockholder, by giving notice not later than the end of the
succeeding 10-day period.

                                       4

<PAGE>

                  (c)      In the event that the purchase of, or the payment
for, some or all of the shares of Common Stock referred to in Section 3.1(a)
hereof by Endo LLC is prohibited under Article V hereof, subject to Section
3.1(b) hereof, an Initial Management Stockholder may elect, at his or her
option, to purchase some or all of such shares of Common Stock, within 20 days
of the determination by Endo LLC that its purchase of, or its payment for, such
shares would be prohibited by Article V hereof.

                  2.2      Notice. If Endo LLC desires to purchase shares of
Common Stock from a Management Stockholder pursuant to Section 3.1 hereof, it
shall notify such Management Stockholder not more than 30 days after the
occurrence of the event giving rise to Endo LLC's right to acquire such
Management Stockholder's shares of Common Stock (or in the case of the
Management Stockholder's death, it shall notify such Management Stockholder's
estate within 30 days of notice to Endo LLC of the Management Stockholder's
death). If Endo LLC does not deliver such notice within such 30-day period and
Kelso (or its designee) desires to purchase such shares, then Kelso (or its
designee) shall notify such Management Stockholder not later than the end of the
succeeding 10-day period.

                  2.3      Payment.

                  (a)      Subject to Article V and Section 3.4 hereof, payment
for shares of Common Stock purchased pursuant to Section 3.1(a) and (b) hereof
shall be made on the date that is (i) in any case in which the price to be paid
for such shares may only be the Carrying Value thereof, the 30th business day
following the date on which notice is given pursuant to Section 3.2 hereof, or
(ii) in all other cases, the 15th business day following the date of the
determination of Fair Market Value pursuant to Section 4.1 hereof.

                  (b)      If the termination of employment of such Management
Stockholder is as a result of his or her resignation without Good Reason, and:

                           (i)      if the date of termination of employment
                  occurs prior to December 1, 2002, then the purchase price of
                  the purchased shares shall be paid within 15 days following
                  the surrender of the certificates representing the purchased
                  shares, and

                           (ii)     if the date of termination of employment
                  occurs on or after December 1, 2002, then the portion of the
                  purchase price of the

                                       5

<PAGE>

                  purchased shares equal to the Carrying Value of such shares on
                  the date of termination of employment shall be paid by the
                  15th day following the surrender of the certificates
                  representing the purchased shares and the remainder shall be
                  paid on the last day of the 18th month following the date of
                  termination of employment.

                  (c)      Notwithstanding the foregoing, in the event that the
termination of employment of a Management Stockholder giving rise to Endo LLC's
right to acquire such Management Stockholder's shares of Common Stock results
from the death or Disability of such Management Stockholder prior to December 1,
2002, then such Management Stockholder shall have the right to elect (which
election shall be irrevocable), within 90 days of the receipt of the notice
specified in Section 3.2 hereof, to defer the effectiveness of Endo LLC's
purchase right with respect to all or any portion of such Management
Stockholder's shares of Common Stock until December 1, 2002. Notwithstanding the
foregoing, no such election may be made by such Management Stockholder with
respect to a portion of such Management Stockholder's shares of Common Stock
unless such election is made with respect to at least one-third of the shares of
Common Stock owned by such Management Stockholder at the time of such
termination of employment. If a Management Stockholder shall fail to make an
election with respect to when Endo LLC's purchase right shall be effective, such
Management Stockholder shall be deemed to have elected to have Endo LLC's
purchase right be effective immediately with respect to all of such Management
Stockholder's shares of Common Stock.

                  In the event Endo LLC's purchase right with respect to all or
any portion of any shares of Common Stock is not effective until December 1,
2002 by reason of the election made by a Management Stockholder under this
Section 3.3(c), December 1, 2002 shall be deemed to be the date of termination
for purposes of determining the purchase price to be paid for the shares of
Common Stock to be purchased after December 1, 2002. Endo LLC shall, subject to
Article V hereof, pay to such Management Stockholder whose employment so
terminates the Fair Market Value of such shares by the 15th day following the
date of determination of Fair Market Value with respect to such deemed
termination date.

                  (d)      Any payments based on Fair Market Value required to
be made by Endo LLC under this Section 3.3 shall accrue interest at 6% simple
interest per annum on the amounts not paid from the date of termination of
employment (or the date of deemed termination, including with respect to the
election made pursuant to Section 3.3(c) hereof) to the date Endo LLC makes such
payments.

                                       6

<PAGE>

                  2.4      Postponement, etc.

                  (a)      The date of payment and closing of any purchase and
sale under this Article III may be postponed to the extent necessary to permit
such purchase and sale under the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended, and the regulations promulgated thereunder, if applicable to
such sale. No party shall be required to consummate any purchase and sale under
this Article III until such time as such transaction would not violate
applicable law, other than violations which would not have a direct or indirect
material adverse effect on such party.

                  (b)      Notwithstanding anything to the contrary in this
Article III, in no event shall any sale of Common Stock that was received by a
Management Stockholder upon the exercise of an employee stock option occur prior
to the six-month anniversary of such exercise.

                                   ARTICLE III

                                 PURCHASE PRICE

                  3.1      Fair Market Value.

                  (a)      Fair Market Value. For the purposes of this
Agreement, the "Fair Market Value" of any share of Common Stock being purchased
by or sold to Endo LLC or Kelso (or its designees) pursuant to this Agreement
shall be the average for the ten consecutive trading days prior to such
transaction of the last sales price for a share of Common Stock on the principal
securities exchange on which the Common Stock is then listed or, if the Common
Stock is not so listed, on the National Association of Securities Dealers
Automated Quotation System or, if not so quoted, on the principal market on
which the Common Stock is then traded.

                  (b)      Notice to Stockholders. After notice has been given
pursuant to Section 2.2, 3.2 or 6.3 hereof, Endo LLC shall promptly deliver a
letter setting forth the Fair Market Value to Kelso and to each Management
Stockholder whose Common Stock is to be purchased pursuant to Section 2.1, 3.1
or 6.3 hereof.

                  3.2      Carrying Value. For the purposes of Sections 3.1 and
6.5 hereof, "Carrying Value" of any share of Common Stock being purchased by
Endo

                                       7

<PAGE>

LLC shall be equal to the price paid by the selling Management Stockholder for
any such share.

                  3.3      Certain Defined Terms. As used in this Agreement, the
following terms shall have the meanings ascribed to them below, except with
respect to Initial Management Stockholders (and such other Management
Stockholders as determined, from time to time, by resolution of the LLC Board)
with employment agreements with the Company which define such terms differently,
in which case such terms shall have the meanings ascribed to them in such
Initial Management Stockholder's respective employment agreement (or the
employment agreements of such other Management Stockholders as determined, from
time to time, by resolution of the LLC Board):

                  (a)      Cause. The term "Cause" used in connection with a
termination of employment of a Management Stockholder shall mean a termination
of such Management Stockholder's employment by the Company or any of its
subsidiaries due to (i) the continued failure, after written notice, by such
Management Stockholder substantially to perform his or her duties with the
Company or any of its subsidiaries (other than any such failure resulting from
incapacity due to reasonably documented physical illness or injury or mental
illness), (ii) the engagement by such Management Stockholder in serious
misconduct that causes, or in the good faith judgment of the Board may cause,
harm (financial or otherwise) to the Company or any of its subsidiaries
including, without limitation, (A) the disclosure of material secret or
confidential information of the Company or any of its subsidiaries (B) the
potential debarment of the Company or any of its subsidiaries by the U.S. Food
and Drug Administration or any successor agency (the "FDA"), or (C) the
possibility that the registration of the Company or any of its subsidiaries with
the U.S. Drug Enforcement Administration or any successor agency (the "DEA")
could be revoked or an application with the DEA could be denied, (iii) the
potential debarment of such Management Stockholder by the FDA, or (iv) the
material breach by the Management Stockholder of this Agreement or any other
agreement between such Management Stockholder, on the one hand, and the Company
or Kelso, on the other hand.

                  (b)      Good Reason. A termination of a Management
Stockholder's employment with the Company or any of its subsidiaries shall be
for "Good Reason" if such Management Stockholder voluntarily terminates his or
her employment with the Company or any of its subsidiaries as a result of any of
the following:

                                       8

<PAGE>

                           (i)      without the Management Stockholder's prior
         written consent, a material reduction by the Company or any of its
         subsidiaries in his or her current salary, other than any such
         reduction which is part of a general salary reduction or other
         concessionary arrangement affecting all employees or affecting the
         group of employees of which the Management Stockholder is a member;

                           (ii)     the taking of any action by the Company or
         any of its subsidiaries that would substantially diminish the aggregate
         value of the benefits provided him or her under the Company's or any
         such subsidiary's medical, health, accident, disability, life
         insurance, thrift and retirement plans in which he or she was
         participating on the date of his or her execution of this Agreement,
         other than any such reduction that is (A) required by law, (B)
         implemented in connection with a general concessionary arrangement
         affecting all employees or affecting the group of employees of which
         the Management Stockholder is a member or (C) generally applicable to
         all beneficiaries of such plans; or

                           (iii)    the assignment to the Management Stockholder
         of duties inconsistent with his or her status within the Company, or a
         substantial adverse alteration in the nature or status of his or her
         responsibilities from those in effect on the date hereof.

                  (c)      Disability. The termination of the employment of any
Management Stockholder by the Company or any of its subsidiaries shall be deemed
to be by reason of a "Disability" if, as a result of such Management
Stockholder's incapacity due to reasonably documented physical illness or injury
or mental illness, such Management Stockholder shall have been unable for more
than six months within any 12-month period to perform his or her duties with the
Company or any of its subsidiaries on a full time basis and within 30 days after
written notice of termination has been given to such Management Stockholder,
such Management Stockholder shall not have returned to the full time performance
of his or her duties. The date of termination in the case of a termination for
"Disability" shall be the last day of the aforementioned 30-day period.

                                       9

<PAGE>

                                   ARTICLE IV

                            PROHIBITION ON PURCHASES

                  4.1      Prohibited Purchases. Notwithstanding anything to the
contrary herein, Endo LLC shall not be permitted or obligated to purchase any
shares of Common Stock from a Management Stockholder (or make any payment for
any purchased shares of Common Stock) pursuant to Section 2.1 or Section 3.1
hereof to the extent (i) Endo LLC or the Company (if the Company were to be the
sole source of the funds necessary to make any such payment or purchase) is
prohibited from purchasing such shares (or incurring debt to finance the
purchase of such shares or making payment for such purchased shares) by any debt
instruments or other agreements (the "Agreements") entered into by Endo LLC, the
Company or any of their respective subsidiaries or by applicable law, (ii) an
event of default under any Agreement has occurred and is continuing or a
condition exists which would, with notice or lapse of time or both, result in an
event of default under any Agreement or (iii) the purchase of such shares by
Endo LLC or the Company (if the Company were to be the sole source of the funds
necessary to make any such payment or purchase) (including the incurrence of any
debt which in the judgment of the LLC Board is necessary to finance such
purchase or the payment for such purchased shares) (A) could, in the judgment of
the LLC Board, result in the occurrence of an event of default under any
Agreement or create a condition which would or might, with notice or lapse of
time or both, result in an event of default under any Agreement, (B) would, in
the judgment of the LLC Board, be imprudent in view of the financial condition
(present or projected) of Endo LLC and its subsidiaries, if any, taken as a
whole, or the Company and its subsidiaries, taken as a whole, or the anticipated
impact of the purchase of (or payment for) such shares on Endo LLC's, the
Company's (if the Company were to be the sole source of the funds necessary to
make any such payment or purchase) or any of their respective subsidiaries'
ability to meet their respective obligations, including under any Agreement or
(C) could, in the judgment of the LLC Board, constitute a fraudulent conveyance
or transfer or render Endo LLC or the Company (if the Company were to be the
sole source of the funds necessary to make any such payment or purchase)
insolvent under applicable law or violate limitations in the Delaware General
Corporation Law on repurchases of stock. If shares of Common Stock which Endo
LLC has the right or obligation to purchase (or make payment for) on any date
exceed the total amount permitted to be purchased on such date pursuant to the
preceding sentence (the "Maximum Amount"), Endo LLC shall purchase (or pay for)
on such date only that number of shares of Common Stock up to the Maximum Amount
(and shall not be required to purchase more than the

                                       10

<PAGE>

Maximum Amount) in such amounts as the LLC Board shall in good faith determine,
applying the following order of priority:

                  (a)      first, the shares of Common Stock of all Management
Stockholders whose shares of Common Stock are being (or were) purchased by Endo
LLC by reason of termination of employment due to death or Disability up to the
Maximum Amount and, to the extent that the number of shares of Common Stock that
Endo LLC is obligated or has the right to purchase (or pay for) from such
Management Stockholders exceeds the Maximum Amount, such shares of Common Stock
pro rata among such Management Stockholders on the basis of the number of shares
of Common Stock held by each of such Management Stockholders that Endo LLC is
obligated or has the right to purchase (or pay for), and

                  (b)      second, to the extent that the Maximum Amount is in
excess of the amount Endo LLC purchases (or pays for) pursuant to clause (a)
above, the shares of Common Stock of all Management Stockholders whose shares of
Common Stock are being (or were) purchased (or paid for) by Endo LLC by reason
of termination of employment without Cause or due to Retirement or resignation
for Good Reason up to the Maximum Amount and, to the extent that the number of
shares of Common Stock that Endo LLC is obligated or has the right to purchase
from such Management Stockholders exceeds the Maximum Amount, such shares of
Common Stock pro rata among such Management Stockholders on the basis of the
number of shares of Common Stock held by each of such Management Stockholders
that Endo LLC is obligated or has the right to purchase (or pay for), and

                  (c)      third, to the extent the Maximum Amount is in excess
of the amounts Endo LLC purchases (or pays for) pursuant to clauses (a) and (b)
above, the shares of Common Stock of all Management Stockholders whose shares of
Common Stock are being (or were) purchased (or paid for) by Endo LLC for any
other reason up to the Maximum Amount and, to the extent that the number of
shares of Common Stock that Endo LLC is obligated or has the right to purchase
(or pay for) from such Management Stockholders exceeds the Maximum Amount, the
shares of Common Stock of such Management Stockholders in such order of priority
and in such amounts as the LLC Board in its sole discretion shall in good faith
determine to be appropriate under the circumstances.

                  Subject to Sections 2.1(c)and 3.1(c) hereof, notwithstanding
anything to the contrary contained in this Agreement, if Endo LLC is unable to
purchase any Management Stockholder's shares pursuant to Section 2.1 or 3.1 of
this Agreement

                                       11

<PAGE>

by reason of this Article V (or make any payment for any purchased shares), Endo
LLC may nonetheless in the case of Section 3.1 hereof exercise its option to
purchase such shares and in the case of purchases pursuant to Sections 2.1 or
3.1 hereof shall purchase (or make payment for) such shares at the earliest
practicable date permitted under this Article V and any payment therefor shall
accrue simple interest (or if such payment is accruing interest at such time,
shall continue to accrue interest) at 6% per annum from the date such payment
would have been made but for this Article V to the date such payment is actually
made. All payments of interest accrued hereunder shall be paid only at the date
of payment by Endo LLC for the shares of Common Stock being purchased. Any
shares as to which Endo LLC has exercised its right to purchase pursuant to
Section 3.1 hereof may not otherwise be sold by the Management Stockholder
notwithstanding non-payment therefor pursuant to this Article V.

                                    ARTICLE V

                             SALES TO THIRD PARTIES

                  5.1      General. No Management Stockholders shall sell any of
his or her shares of Common Stock to a third party for the term of this
Agreement; provided that such restriction shall not apply to any sale or other
transaction described in clause (i) or (ii) of Section 1.1 hereof or to any sale
pursuant to a Registration under the Act, subject to Article VII hereof. Endo
LLC may not sell the shares of Common Stock it owns to a third party at any time
after the date of this Agreement unless Endo LLC as transferor first complies
with Section 6.4 hereof.

                  5.2      Agreements to Be Bound. Notwithstanding anything
contained in this Article VI, any sale to a third party or any Involuntary
Transfer (as defined in Section 6.3 hereof) to an Involuntary Transferee (as
defined in Section 6.3 hereof) shall be permitted under the terms of this
Agreement only if such third party or Involuntary Transferee, as the case may
be, shall agree in writing to be bound by the terms and conditions of this
Agreement pursuant to an instrument of assumption reasonably satisfactory in
form and substance to Endo LLC.

                  5.3      Involuntary Transfers. In the case of any transfer of
title or beneficial ownership of shares of Common Stock upon default,
foreclosure, forfeit, divorce, court order, or otherwise than by a voluntary
decision on the part of a Management Stockholder (an "Involuntary Transfer"),
Endo LLC shall have the right to purchase such shares pursuant to this Section
6.3. Upon the Involuntary Transfer

                                       12

<PAGE>

of any shares of Common Stock, such Management Stockholder shall promptly (but
in no event later than two days after such Involuntary Transfer) furnish written
notice (the "Notice") to Endo LLC indicating that the Involuntary Transfer has
occurred, specifying the name of the person to whom such shares have been
transferred (the "Involuntary Transferee") and giving a detailed description of
the circumstances giving rise to, and stating the legal basis for, the
Involuntary Transfer. Upon the receipt of the Notice, and for 30 days
thereafter, Endo LLC shall have the right to purchase, and the Involuntary
Transferee shall have the obligation to sell, all, but not less than all, of the
shares of Common Stock acquired by the Involuntary Transferee for a purchase
price equal to the lesser of (i) the Fair Market Value of such shares of Common
Stock on the date of transfer to the Involuntary Transferee and (ii) the amount
of the indebtedness or other liability that gave rise to the Involuntary
Transfer plus the excess, if any, of the Carrying Value of such shares of Common
Stock over the amount of such indebtedness or other liability that gave rise to
the Involuntary Transfer.

                  Notwithstanding the foregoing, the LLC Board may, for good
cause shown by the Management Stockholder who made the Involuntary Transfer,
determine that payment of a purchase price equal to the Fair Market Value of
such shares of Common Stock on the date of transfer to the Involuntary
Transferee would be appropriate under the circumstances, and direct that payment
be made in such amount.

                  Kelso shall have the right to require Endo LLC to assign to
Kelso (or a designee of Kelso) Endo LLC's right to purchase pursuant to this
Section 6.3.

                  5.4      Tag-Along and Drag-Along Rights.

                  (a)      Tag Along Rights. Endo LLC shall not, in any one
transaction or any series of similar transactions not effected through a broker
or over a national securities exchange, Transfer more than 25% of the shares of
Common Stock it owns as of the date of the Merger, except pursuant to Section
5.4(b) hereof, or except in connection with a registered public offering of the
Company's securities or any other capital markets transaction, to any third
party or parties unaffiliated with Endo LLC (a "Third Party"), unless the
Management Stockholders (collectively, the "Offerees"), are offered the right,
at the option of each Offeree, to include in such Transfer to the Third Party
such number of shares of Common Stock then owned by each such Offeree, as
determined in accordance with this Section 5.4(a). If Endo LLC receives from a
Third Party a bona fide offer or offers to Transfer which it intends to accept,

                                       13

<PAGE>

or proposes to Transfer to a Third Party, shares of its Common Stock, Endo LLC
shall provide written notice (the "Tag-Along Notice") to each of the Offerees,
setting forth the consideration per share to be paid by such Third Party and the
other material terms and conditions of such transaction. The Tag-Along Notice
shall offer the Offerees the opportunity to participate in the proposed Transfer
of shares to the Third Party according to the terms and conditions of this
Section 5.4(a) and for the same type of consideration and for an amount of
consideration per share not less than that offered to Endo LLC by the Third
Party. At any time within 20 days after its receipt of the Tag-Along Notice,
each of the Offerees may irrevocably accept the offer included in the Tag-Along
Notice for up to such number of shares of Common Stock as is determined in
accordance with the provisions of this Section 5.4(a) by furnishing written
notice of such acceptance to Endo LLC. Promptly following such acceptance by an
Offeree, each such Offeree shall deliver to Endo LLC the certificate or
certificates representing the shares of Common Stock to be Transferred pursuant
to such offer by such Offeree, together with a limited power-of-attorney
authorizing Endo LLC to sell or otherwise dispose of such shares of Common Stock
pursuant to the proposed Transfer to the Third Party.

                  Each Offeree shall have the right to participate in the
proposed Transfer to the Third Party by Transferring in connection therewith
shares of Common Stock equal to the product of (x) the total number of shares to
be acquired by the Third Party, times (y) a fraction, the numerator of which
shall be the total number of shares of Common Stock then owned by such Offeree,
and the denominator of which shall be the number of shares of Common Stock then
owned by Endo LLC plus the total number of shares of Common Stock then owned by
the Offerees. The maximum number of shares of Common Stock that may be
Transferred by each Offeree to the Third Party in accordance with this Section
5.4(a) shall be the total number of shares of Common Stock then owned by such
Offeree.

                  If within 20 days after the receipt of the Tag-Along Notice,
any Offeree has not accepted the offer contained in the Tag-Along Notice, such
Offeree will be deemed to have waived any and all rights with respect to, or to
participate in, the Transfer of Common Stock described in the Tag-Along Notice
and Endo LLC shall have 45 days in which to Transfer not more than the amount of
Common Stock described in the Tag-Along Notice, for an amount and type of
consideration per share not materially more favorable to Endo LLC than was set
forth in the Tag-Along Notice. If, at the end of 65 days following the receipt
of the Tag-Along Notice, Endo LLC has not completed the Transfer of Common Stock
of Endo LLC and Common Stock of any Offeree, Endo LLC shall return to such
Offeree all certificates representing shares of Common Stock which such Offeree
delivered for Transfer

                                       14

<PAGE>

pursuant to this Section 6.4(a), and all the restrictions on sale or other
disposition contained in this Agreement with respect to Common Stock then or
thereafter owned by the Offeree shall again be in effect.

                  As promptly as practicable (but in no event later than 5 days)
after the consummation of the Transfer of Common Stock of Endo LLC and Common
Stock of the Offerees to the Third Party in accordance with this Section 5.4(a),
Endo LLC shall notify the Offerees thereof, shall remit to each of the Offerees
the total consideration in respect of the shares of Common Stock of such Offeree
which were so Transferred, and shall furnish such other evidence of the
completion and time of completion of such Transfer and the terms thereof as may
be reasonably requested by the Offerees.

                  (b)      Drag-Along Rights. If Endo LLC shall propose to
Transfer at least 60% of all shares of Common Stock then owned by Endo LLC to a
Third Party, then (in addition to the rights of the Management Stockholders to
participate in such Transfer pursuant to Section 5.4(a) hereof) Endo LLC may, at
its option, require the Management Stockholders (collectively, the "Remaining
Holders"), include in such Transfer to the Third Party such number of shares of
Common Stock then owned by such Remaining Holder, as determined in accordance
with this Section 5.4(b).

                  Endo LLC shall send written notice (the "Drag-Along Notice")
of the exercise of its rights pursuant to this Section 5.4(b) to each of the
Remaining Holders, setting forth the consideration per share to be paid by the
Third Party and the other material terms and conditions of such transaction. The
Drag-Along Notice shall state that the Remaining Holders shall be required to
participate in the proposed Transfer of shares of Common Stock to the Third
Party according to the terms and conditions of this Section 5.4(b) and for the
same type of consideration and for an amount of consideration per share not less
than that offered to Endo LLC by the Third Party. Within 15 days following the
receipt of the Drag-Along Notice, each of the Remaining Holders shall deliver to
a representative of Endo LLC designated in the Drag-Along Notice certificates
representing all shares of Common Stock held by such Remaining Holder, duly
endorsed, together with all other documents required to be executed in
connection with such transaction. In the event that any Remaining Holder should
fail to deliver such certificates to Endo LLC, the Company shall cause the books
and records of the Company to show that such shares are bound by the provisions
of this Section 5.4(b) and that such shares may be Transferred only to the Third
Party.

                  Each Remaining Holder shall be required to participate in the
proposed Transfer to the Third Party by Transferring in connection therewith
shares

                                       15

<PAGE>

of Common Stock equal to the product of (x) the total number of shares to be
acquired by the Third Party, times (y) a fraction, the numerator of which shall
be the total number of shares of Common Stock then owned by such Remaining
Holder, and the denominator of which shall be the total number of shares of
Common Stock then owned by Endo LLC plus the total number of shares of Common
Stock then owned by the Remaining Holders. The maximum number of shares of
Common Stock that may be Transferred by each Remaining Holder to the Third Party
in accordance with this Section 5.4(b) shall be the total number of shares of
Common Stock then owned by such Remaining Holder.

                  If, within 120 days after Endo LLC gave the Drag-Along Notice,
it shall not have completed the Transfer of all the shares of Common Stock of
the Remaining Holders in accordance with this Section 5.4(b), Endo LLC shall
return to each of the Remaining Holders all certificates representing shares of
Common Stock that such Remaining Holder delivered for Transfer pursuant hereto
and that were not purchased pursuant to this Section 5.4(b).

                  Promptly (but in no event later than 5 days) after the
consummation of the Transfer of Common Stock of Endo LLC and Remaining Holders
pursuant to this Section 5.4(b), Endo LLC shall give notice thereof to the
Remaining Holders, shall remit to each of the Remaining Holders the total
consideration in respect of the shares of Common Stock of such Remaining Holder
which were so transferred, and shall furnish such other evidence of the
completion and time of completion of such Transfer and the terms thereof as may
be reasonably requested by such Remaining Holders.

                                   ARTICLE VI

                               REGISTRATION RIGHTS

                  6.1 Incidental Registration. If Endo LLC, pursuant to that
certain registration rights agreement, dated as of July 17, 2000, by and between
the Company and Endo LLC (the "Endo LLC Registration Rights Agreement"), demands
that the Company register any of its shares of Common Stock or any other of its
common equity securities (collectively, "Other Securities") under the Act for
sale for cash to the public under the Act, then Endo LLC will at such time make
reasonable efforts to give prompt written notice to each Management Stockholder
or any of their respective Permitted Transferees (each, a "Holder") of its
intention to do so and of the rights of such Holder under this Section 6.1, 5
business days after the Company's

                                       16

<PAGE>

filing of the registration statement relating to such demand registration. Such
notice shall offer each such Holder the opportunity to include in such
registration statement such number of shares of Common Stock as such Holder may
request, in accordance with this Section 6.1. Upon the written request of a
Holder made within 10 days after the receipt of Endo LLC's notice (which request
shall specify the number of shares of Common Stock intended to be disposed of
and the intended method of disposition thereof), Endo LLC will use its best
efforts to cause the Company to effect, in connection with the registration of
the Other Securities, the registration under the Act of all shares of Common
Stock which the Company has been so requested to register, to the extent
required to permit the disposition (in accordance with such intended methods of
disposition) of such shares of Common Stock so requested to be registered,
provided that:

                  (a) if, at any time after Endo LLC has given such written
notice of the Company's intention to register any Other Securities pursuant to a
demand by Endo LLC and prior to the effective date of the registration statement
filed in connection with such demand registration, Endo LLC shall determine for
any reason not to demand such registration, Endo LLC shall give written notice
of such determination to the Holders, and thereupon the Company shall be
relieved of its obligation to register the shares of Common Stock requested to
be registered in connection with the demand registration of such Other
Securities;

                  (b) if the registration referred to in the first sentence of
Section 6.1 hereof is to be an underwritten registration on behalf of Endo LLC,
and the managing underwriter(s) advises the Company in writing that, in such
firm's opinion, such offering would be materially and adversely affected by the
inclusion therein of any of the Common Stock requested to be included therein,
the Company shall include in such registration: (i) first, all securities for
which Endo LLC has demanded registration ("Endo LLC Securities"), (ii) second,
up to the full number of shares of Common Stock requested to be included in such
registration by the Management Stockholders and the "Employee Stockholders" (as
such term is defined in that certain Amended and Restated Employee Stockholders
Agreement, dated as of July 14, 2000, by and among the Company, Kelso, Endo LLC
and the Employee Stockholders, as the same shall be amended from time to time),
which, in the good faith opinion of such firm, can be sold without so materially
and adversely affecting such offering (and, if less than the full number of such
shares of Common Stock, allocated pro rata among the Management Stockholders and
the Employee Stockholders on the basis of the total number of shares of Common
Stock requested to be included therein by the Management Stockholders and the
Employee Stockholders); provided, however, that with respect to the Management
Stockholders

                                       17

<PAGE>

and the Employee Stockholders, if the managing underwriter(s) in connection with
such registration determines that such offering would be materially and
adversely affected by the inclusion of Common Stock owned by the Management
Stockholders and the Employee Stockholders for any reason, such managing
underwriter(s) may in its sole discretion exclude all or, part of the Common
Stock requested to be included therein by the Management Stockholders and the
Employee Stockholders on a pro rata basis, unless the Company and the managing
underwriter(s) shall agree to non pro rata treatment; and (iii) third, an amount
of other securities, if any, requested to be included therein in excess of the
number or dollar amount of Company Securities and Common Stock of the Holders
which, in the opinion of such firm, can be so sold without materially and
adversely affecting such offering (allocated among the holders of such other
securities in such proportions as such holders and the Company may agree); and

                  (c) no registration of Common Stock effected under this
Section 6.1 shall relieve the Company of its obligation to effect a registration
of shares of Common Stock pursuant to the Endo LLC Registration Rights
Agreement.

                  (d) Promptly following its acceptance of the offer to
participate in the demand registration, each Management Stockholder shall
deliver to Endo LLC the certificate or certificates representing the shares of
Common Stock to be Transferred pursuant to such offer by such Management
Stockholder, together with a limited power-of-attorney and other customary
custodial agreements authorizing Endo LLC to sell or otherwise dispose of such
Management Stockholder shares of Common Stock pursuant to the proposed demand
registration.

                  6.2      Expenses. The Company will pay all expenses in
connection with any registration pursuant to this Article VII (including any
registration not consummated as contemplated by Section 7.1(a) hereof) and any
other actions that may be taken in connection with any such registration as
contemplated by this Article VII; provided, however, that the Company will not
be obligated to pay underwriting discounts or commissions or transfer taxes, if
any, relating to the sale or disposition of shares sold pursuant to any such
registration.

                  6.3      Holdback and Other Agreements.

                  (a)      If and whenever the Company proposes to register any
of its equity securities under the Securities Act for its own account (other
than on Form S-4 or S-8 or any successor form) or is required to use its best
efforts to effect the

                                       18

<PAGE>

registration of any shares of Common Stock under the Securities Act pursuant to
Section 7.1 hereof, each Holder agrees by acquisition of such shares of Common
Stock not to effect any sale or distribution, including any sale pursuant to
Rule 144 under the Securities Act, or to request registration under Section 7.1
hereof of any shares of Common Stock within seven days prior to and 90 days
(unless advised by the managing underwriter that a longer period, not to exceed
180 days, is required, or such shorter period as the managing underwriter for
any underwritten offering may agree) after the effective date of the
registration statement relating to such registration, except as part of such
registration or unless, in the case of a private sale of distribution, the
transferee agrees in writing to be subject to this Section 7.3. If requested by
such managing underwriter, each holder of shares of Common Stock agrees to
execute a holdback agreement, in customary form, consistent with the terms of
this Section 7.3(a).

                  (b)      The Company agrees not to effect any public sale or
distribution of its equity securities or securities convertible into or
exchangeable or exercisable for any of such securities within seven days prior
to and 90 days (unless advised in writing by the managing underwriter that a
longer period, not to exceed 180 days, is required, or such shorter period as
the managing underwriter for any underwritten offering may agree) after the
effective date of any registration statement filed pursuant to Section 7.1
hereof (except (i) as part of such registration, (ii) as permitted by the
related underwriting, (iii) pursuant to an employee equity compensation plan,
(iv) pursuant to an acquisition or strategic relationship, bank or equipment
financing or similar transaction or (v) pursuant to a registration on Form S-4
or S-8 or any successor form). In addition, upon the request of the managing
underwriter, the Company shall use its best efforts to cause each holder of its
equity securities or any securities convertible into or exchangeable or
exercisable for any of such securities, whether outstanding on the date of this
Agreement or issued at any time after the date of this Agreement (other than any
such securities acquired in a public offering), to agree not to effect any such
public sale or distribution of such securities during such period, except as
part of any such registration if permitted, and to cause each such holder to
enter into a similar agreement to such effect with the Company.

                  6.4      Indemnification. The Company may require as a
condition to including any Common Stock in any registration statement filed
pursuant to Section 7.1 hereof that the Company shall have received an
undertaking from the prospective seller of Common Stock to indemnify directors,
officers and other persons, if any, who may control the Company within the
meaning of the Act with respect to any statement or alleged statement in or
omission or alleged omission from such registra-

                                       19

<PAGE>

tion statement, prospectus contained therein, or any amendment or supplement
thereto, if such statement or alleged statement or such omission or alleged
omission was made in reliance upon and in conformity with written information
furnished to the Company through an instrument duly executed by such prospective
seller of Common Stock specifically stating that it is for use in the
preparation of such registration statement, prospectus contained therein, or
amendment or supplement thereto. The parties hereto hereby acknowledge and agree
that, unless otherwise expressly agreed to in writing by such prospective seller
to the contrary, for all purposes of this agreement the only information
furnished or to be furnished by such prospective seller, in its capacity as
such, to the Company for use in any registration statement, prospectus contained
therein, or any amendment or supplement thereto are statements specifically
relating to (i) transactions between the prospective seller and its affiliates,
on the one hand, and the Company, on the other hand, (ii) the beneficial
ownership of shares of Common Stock by the prospective seller and its affiliates
and (iii) the name and address of the prospective seller and its affiliates.

                                   ARTICLE VII

                                CHARTER DOCUMENTS

                  7.1      Charter Documents. The Company has previously
furnished to the Management Stockholders copies of its Certificate of
Incorporation and By-Laws, each as shall be in effect on the date of the closing
of the Merger (the "Charter Documents"). From and after the date of this
Agreement, each Management Stockholder shall vote its shares of voting stock of
the Company, at any regular or special meeting of stockholders of the Company or
in any written consent executed in lieu of such a meeting of stockholders, and
shall take all actions necessary, to ensure that the Charter Documents do not,
at any time, conflict with the provisions of this Agreement.

                                  ARTICLE VIII

                                   TERMINATION

                  8.1      Sale of the Company. This Agreement shall terminate
(a) in the event of a sale of the Company or all or substantially all of its
assets to a party (whether by merger, stock sale or otherwise) other than Endo
LLC or one of its

                                       20

<PAGE>

affiliates or (b) in the event that all parties to this Agreement cease to own
any shares of Common Stock or any interest therein. In the event that Endo LLC
shall come to own less than five percent of the outstanding Common Stock, this
Agreement shall also terminate, except with respect to Article VII hereof which
shall survive such termination indefinitely.

                  8.2      Cessation of Ownership of Stock. Any party to, or
person or entity who is subject to, this Agreement (other than the Company and
Kelso) which ceases to own shares of Common Stock or any interest therein shall
cease to be a party to, or person or entity who is subject to, this Agreement
and thereafter shall have no rights or obligations hereunder.

                  8.3      Other Termination Events.

                  (a)      This Agreement may be terminated by the affirmative
vote of the members of Endo LLC owning a majority of the issued and outstanding
membership interests in Endo LLC.

                  (b)      Notwithstanding anything to the contrary contained
herein, every provision of this Agreement, other than the provisions contained
in Section 6.5 and Article VII hereof, shall terminate upon the fifteenth
anniversary of this Agreement.

                                   ARTICLE IX

                            MISCELLANEOUS PROVISIONS

                  9.1      Stock Certificate Legend. A copy of this Agreement
shall be filed with the Secretary of the Company and kept with the records of
the Company. Each certificate representing shares of Common Stock owned by the
Management Stockholders shall bear upon its face the following legend:

         "THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR
         INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
         1933 (THE "ACT"), AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED,
         HYPOTHECATED OR OTHERWISE DISPOSED OF UNLESS AND UNTIL REGISTERED UNDER
         THE ACT AND

                                       21

<PAGE>

         ANY APPLICABLE STATE SECURITIES LAWS OR UNLESS, IN THE OPINION OF
         COUNSEL TO THE HOLDER, WHICH COUNSEL MUST BE, AND THE FORM AND
         SUBSTANCE OF WHICH OPINION ARE, SATISFACTORY TO THE ISSUER, SUCH OFFER,
         SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION, TRANSFER OR OTHER DISPOSITION
         IS EXEMPT FROM REGISTRATION OR IS OTHERWISE IN COMPLIANCE WITH THE ACT,
         SUCH LAWS AND THE AMENDED AND RESTATED STOCKHOLDERS AGREEMENT, DATED AS
         OF JULY __, 2000."

                  All Management Stockholders shall be bound by the requirements
of such legends to the extent that such legends are applicable. Upon a
registration under the Act of any shares of Common Stock, the certificate
representing such shares shall be replaced, at the expense of the Company, with
certificates not bearing the legend required by this Section 10.1.

                  9.2      Option Plans. Pursuant to the Option Plans, the
Company has required that participants thereunder must become parties to this
Agreement upon exercise of the options and that they will be "Management
Stockholders" hereunder with respect to such shares. In addition, Endo LLC,
notwithstanding any requirement set forth in Section 10.4 hereof, can determine
that any options granted pursuant to the Option Plans and outstanding and vested
as of the option holder's termination of employment with the Company and its
subsidiaries shall be deemed to be Common Stock for purposes of Sections 2 and 3
hereof; provided, however, that appropriate adjustments shall be made to reflect
the existence of an exercise price for such options.

                  9.3      New Management Stockholders. Each of the Management
Stockholders hereby agrees that the Company may require that any executive
employee of the Company or any of its subsidiaries who after the date of this
Agreement is offered shares of Common Stock shall, as a condition precedent to
the acquisition of such shares of Common Stock, become a party to this Agreement
by executing the same and delivering it to the Company at its address specified
in Section 10.11 hereof. Upon such execution and delivery, such executive
employee shall be a "Management Stockholder" for all purposes of this Agreement.

                  9.4      No Other Arrangements or Agreements. Each Management
Stockholder hereby represents, warrants and covenants to Endo LLC and to each

                                       22

<PAGE>

other Management Stockholder that, except for, if applicable, the exchange
agreement entered into on December 1, 1997, by and between the Company and each
Management Stockholder (collectively, the "Exchange Agreements") and the
exchange agreement entered into as of the date of this Agreement, by and between
Endo LLC and each Management Stockholder (collectively, the "LLC Exchange
Agreements"), he or she has not entered into or agreed to be bound by, and will
not enter into or agree to be bound by, any other arrangements or agreements of
any kind with any other party with respect to the shares of Common Stock,
including, but not limited to, arrangements or agreements with respect to the
acquisition, disposition or voting of shares of Common Stock (whether or not
such agreements and arrangements are with the Company, other Management
Stockholders or holders of Common Stock that are not parties to this Agreement).
Each Management Stockholder represents, warrants and covenants to Endo LLC and
to each other Management Stockholder that it has not entered into or agreed to
be bound by, and will not enter into or agree to be bound by, any voting
agreements with respect to its shares of Common Stock.

                  9.5      Amendment and Modification. This Agreement may be
amended, modified or supplemented only with the written consent of (i) Kelso and
(ii) the Management Stockholders owning a majority of the outstanding Common
Stock then owned by all Management Stockholders; provided that Endo LLC may, at
any time and from time to time, in its sole discretion, release all or a portion
of any Management Stockholder's shares of Common Stock from the benefits and
obligations under this Agreement; provided, however, that the shares of Common
Stock held by any Management Stockholder will, notwithstanding any such release,
continue to have the benefit of the provisions of this Agreement unless counsel
for Endo LLC or the Company provides a written notice that, in the view of such
counsel, such Management Stockholder is free to sell publicly all of the shares
of Common Stock held by such Management Stockholder at such time either (a)
without registration under the Act or (b) pursuant to a then effective
registration statement under the Act; provided further that Endo LLC and the
Company hereby agree to take all reasonable steps to facilitate any such sale at
any time, including providing legal opinions and any other comfort required by
the transfer agent.

                  9.6      Assignment. The provisions of this Agreement shall be
binding upon and inure to the benefit of the parties hereto and their respective
heirs, legal representatives, successors and assigns; provided, however, that
none of Endo LLC, the Company and any Management Stockholder shall assign any of
its rights or obligations pursuant to this Agreement without the prior written
consent of Kelso.

                                       23

<PAGE>

Endo LLC, with the prior written consent of Kelso, shall have the right, but not
the obligation, to assign any of its rights, and delegate any of its
obligations, to purchase any shares of Common Stock of any Management
Stockholder pursuant to Sections 2 and 3 hereof to any affiliate of Endo LLC,
any one or more persons or entities who are or become parties to this Agreement
or any employee stock ownership plan that the Company may have (or any
combination of the foregoing). In the case of Permitted Transferees, third
parties and Involuntary Transferees, such Permitted Transferees, third parties
or Involuntary Transferees, as the case may be, shall be deemed the Management
Stockholder hereunder for purposes of obtaining the benefits or enforcing the
rights of such Management Stockholder hereunder; provided, however, that no
Permitted Transferee, third party or Involuntary Transferee, as the case may be,
shall derive any rights under this Agreement unless and until such Permitted
Transferee, third party or Involuntary Transferee, as the case may be, has
delivered to Endo LLC a valid undertaking to become, and becomes, bound by the
terms of this Agreement to which the transferring Management Stockholder is
subject.

                  9.7      Recapitalizations, Exchanges, etc. Affecting the
Common Stock. Except as otherwise provided herein, the provisions of this
Agreement shall apply to the full extent set forth herein with respect to (i)
the shares of Common Stock and (ii) any and all shares of capital stock of the
Company or any successor or assign of the Company (whether by merger,
consolidation, exchange, sale of assets or otherwise), which may be issued in
respect of, in exchange for, or in substitution for the shares of Common Stock,
by reason of any stock dividend, split, reverse split, combination,
recapitalization, reclassification, merger, consolidation or otherwise.
References to the "Company" set forth herein shall be deemed to refer to any
such successor or assign and such entity shall execute an appropriate instrument
of assumption agreeing to be bound by the terms hereof. Except as otherwise
provided herein, this Agreement is not intended to confer upon any person,
except for the parties hereto, any rights or remedies hereunder.

                  9.8      Transfer of Common Stock. If at any time Endo LLC
purchases any shares of Common Stock pursuant to this Agreement, Endo LLC may
pay the purchase price determined under this Agreement for the shares of Common
Stock it purchases by wire transfer of funds or Endo LLC check in the amount of
the purchase price, and upon receipt of payment of such purchase price or,
pursuant to Section 2.3, Section 3.3 or Article V hereof, any portion thereof,
the selling Management Stockholder shall deliver to Endo LLC the certificates
representing the number of shares of Common Stock being purchased in a form
suitable for transfer, duly endorsed in blank, and free and clear of any lien,
claim or encumbrance. In the event

                                       24

<PAGE>

that any Management Stockholder refuses or otherwise fails to deliver, in
accordance with the preceding sentence, certificates representing the number of
shares of Common Stock being purchased, the shares of Common Stock purchased
from such Management Stockholder shall (notwithstanding such refusal or failure)
be deemed, upon receipt by such Management Stockholder of the purchase price
therefor, to not be outstanding for any purposes. Notwithstanding anything in
this Agreement to the contrary, Endo LLC shall not be required to make any
payment for shares of Common Stock purchased hereunder until delivery to it of
the certificates representing such shares. If Endo LLC is purchasing less than
all the shares of Common Stock represented by a single certificate, the Company,
after Endo LLC makes such purchase, shall deliver to the selling Management
Stockholder a certificate for any unpurchased shares of Common Stock.

                  9.9      Further Assurances. Each party hereto or person or
entity subject hereto shall do and perform or cause to be done and performed all
such further acts and things and shall execute and deliver all such other
agreements, certificates, instruments and documents as any other party hereto or
person or entity subject hereto may reasonably request in order to carry out the
intent and accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.

                  9.10     Governing Law. This Agreement and the rights and
obligations of the parties hereunder and the persons subject hereto shall be
governed by, and construed and interpreted in accordance with, the law of the
State of Delaware, without giving effect to the choice of law principles
thereof.

                  9.11     Invalidity of Provision. The invalidity or
unenforceability of any provision of this Agreement in any jurisdiction shall
not affect the validity or enforceability of the remainder of this Agreement in
that jurisdiction or the validity or enforceability of this Agreement, including
that provision, in any other jurisdiction.

                  9.12     Notices. All notices and other communications
hereunder shall be in writing and, unless otherwise provided herein, shall be
deemed duly given if delivered personally, telecopied (which is confirmed) or
sent by registered or certified mail (postage prepaid, return receipt requested)
or by Fedex or other similar courier service to the parties at the following
addresses (or at such other address as the person or entity to whom notice is
given may have previously furnished to the others in writing as set forth in
this Section 10.12 (provided that any change of address shall be effective only
upon receipt thereof)):

                                       25

<PAGE>

                           (a)      If to the Company, to it at:

                                    Endo Pharmaceuticals Holdings Inc.
                                    100 Painters Drive
                                    Chadds Ford, Pennsylvania 19317
                                    Attn: Carol A. Ammon

                                    with a copy to:

                                    Kelso & Company
                                    320 Park Avenue, 24th Floor
                                    New York, New York 10022
                                    Attention: James J. Connors, II
                                    Telecopy No.: (212) 223-2379

                           (b)      if to a Management Stockholder, as listed on
                                    the signature page hereto, or, if not so
                                    listed, to it at its address as reflected in
                                    the stock records of the Company, or as such
                                    Management Stockholder shall designate to
                                    the Company in writing, with a copy to Kelso
                                    at its address indicated below (provided
                                    that any such designation shall be effective
                                    only upon receipt thereof).

                           (c)      If to Endo LLC, to it at:

                                    Endo Pharma LLC
                                    c/o Kelso & Company
                                    320 Park Avenue, 24th Floor
                                    New York, New York 10022
                                    Attention: James J. Connors, II
                                    Telecopy No.: (212) 223-2379

                  9.13     Headings; Execution in Counterparts. The headings and
captions contained herein are for convenience and shall not control or affect
the meaning or construction of any provision hereof. This Agreement may be
executed in any number of counterparts, each of which shall be deemed to be an
original and which together shall constitute one and the same instrument.

                                       26

<PAGE>

                  9.14     Entire Agreement; Effect on Certain Other Agreements.
This Agreement, the Exchange Agreements and the LLC Exchange Agreements embody
the entire agreement and understanding of the parties hereto in respect of the
subject matter contained herein. There are no restrictions, promises,
representations, warranties, covenants or undertakings relating to the shares of
Common Stock, other than those expressly set forth or referred to herein or in
the Exchange Agreements or the LLC Exchange Agreements. This Agreement, the
Exchange Agreements and the LLC Exchange Agreements supersede all prior
agreements and understandings among the parties with respect to such subject
matter.

                  9.15     Injunctive Relief. The Company, Endo LLC and the
Management Stockholders hereby acknowledge that they each shall be irreparably
damaged in the event this Agreement is not specifically enforced. Each of the
parties therefore agrees that in the event of a breach of any provision of this
Agreement, the aggrieved party may elect to institute and prosecute proceedings
in any court of competent jurisdiction to enforce specific performance or to
enjoin the continuing breach of this Agreement. Such remedies shall, however, be
cumulative and not exclusive, and shall be in addition to any other remedy which
the Company, Endo LLC or the Management Stockholders may have. Each Management
Stockholder hereby irrevocably submits to the non-exclusive jurisdiction of the
state and federal courts in New York and Delaware for the purposes of any suit,
action or other proceeding arising out of or based upon this Agreement or the
subject matter hereof. Each Management Stockholder hereby consents to service of
process by mail made in accordance with Section 10.12 hereof.

                  9.16     Attorneys' Fees. If any legal action or any
arbitration or other proceeding is brought for the enforcement of this
Agreement, or because of an alleged dispute, breach, default or
misrepresentation in connection with any of the provisions of this Agreement,
the successful or prevailing party or parties shall be entitled to recover such
reasonable attorneys' fees and other costs incurred in that action or
proceeding, in addition to any other relief to which it or they may be entitled,
as may be ordered in connection with such proceeding.

                                       27

<PAGE>

                  IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be duly executed as of the date first above written.

                           ENDO PHARMACEUTICALS HOLDINGS INC.

                           By:     /S/ JEFFREY R. BLACK
                              -------------------------
                                   Name:  Jeffrey R. Black
                                   Title: Chief Financial Officer

                           KELSO INVESTMENT ASSOCIATES V, L.P.

                           By: Kelso Partners V, L.P., General Partner

                                   By:      /S/ PHILIP E. BERNEY
                                      --------------------------
                                            Name: Philip E. Berney
                                            Title: General Partner

                           ENDO PHARMA LLC

                           By:     /S/ JEFFREY R. BLACK
                              -------------------------
                                   Name:  Jeffrey R. Black
                                   Title: Chief Financial Officer

                           MANAGEMENT STOCKHOLDER

                           By: /s/ CAROL A. AMMON
                               ------------------
                               Name:  Carol A. Ammon
                               Title: Chairman & Chief Executive Officer

                           MANAGEMENT STOCKHOLDER

                           By:     /S/ JEFFREY R. BLACK
                              -------------------------
                                   Name:  Jeffrey R. Black
                                   Title: Senior Vice President and Chief

                                       28

<PAGE>

                                          Financial Officer

                           MANAGEMENT STOCKHOLDER

                           By:     /S/ PETER A. LANKAU
                              ------------------------
                                   Name:  Peter A. Lankau
                                   Title: President and Chief Operating Officer

                           MANAGEMENT STOCKHOLDER

                           By:     /S/ DAVID A. H. LEE
                              ------------------------
                                   Name:  David A. H. Lee
                                   Title: Executive Vice President, R&D and
                                          Regulatory Affairs

                           MANAGEMENT STOCKHOLDER

                           By:     /S/ MARIANN T. MACDONALD
                              -----------------------------
                                   Name:  Mariann T. MacDonald
                                   Title: Executive Vice President

                           MANAGEMENT STOCKHOLDER

                           By:     /S/ CAROLINE B. MANOGUE
                              ----------------------------
                                   Name:  Caroline B. Manogue
                                   Title: Senior Vice President, General
                                          Counsel & Secretary

                                       29

<PAGE>

                  The undersigned, by its signature below hereby becomes a party
to the Amended and Restated Stockholders Agreement, dated as of July __, 2000,
among Endo Pharmaceuticals Holdings Inc. and certain of its stockholders (the
"Stockholders Agreement") pursuant to Section 10.3 thereof and agrees to be
bound by the terms of the Stockholders Agreement and, for all purposes thereof,
to be a "Management Stockholder".

                  IN WITNESS WHEREOF, the undersigned has executed this
instrument as of the ____ day of ___________ , 20__.

                                   _____________________________________________
                                                   Signature

                                   _____________________________________________
                                                  Print Name

                                       30EX-10.1 AGREEMENT DATED 08/14/03

 

EXHIBIT 10.1

AGREEMENT

     This Agreement (“Agreement”) is made and entered into as of August 14,
2003, by and between Michael Herman, an individual resident of the state of
Colorado (“Herman”) and SunAir Electronics, Inc., a Florida corporation
(“SunAir”).

     WHEREAS, Herman proposes to acquire certain shares of SunAir (the
“Acquisition”) held by the Robert Uricho, Jr. Revocable Living Trust, SunTrust
Bank South Florida and Shirley Uricho, Trustees (the “Trust”).

     WHEREAS, the Trust owns approximately 54% of SunAir and public
shareholders own approximately 46% of SunAir on an undiluted basis; and Herman
desires that the Board of Directors of SunAir, approve the Acquisition in order
to avoid the adverse voting rights consequences which otherwise would result
under the Florida Control Share Act, Fla. Stat.ss.607.0902; and

     WHEREAS, SunAir desires that Herman provide certain commitments to ensure
that the interests of the SunAir minority shareholders are protected, including
by means of ensuring the continuity of the Board of Directors and management;
and

     NOW, THEREFORE, in consideration of the premises and agreement and
covenants contained herein, the parties hereto do hereby agree as follows:

     1.     Covenants. Based on the fact that the Board of Directors of SunAir has
conditionally approved the Acquisition, Herman agrees to take all necessary
action, to the extent under his control, to implement the following on and
after the effective date of the Acquisition.

          (a)  That the existing Board of Directors of SunAir remain as currently
comprised and complete their terms of office, with the exception that: (i)
Shirley Uricho shall resign on the effective date of the Acquisition, and on
such date Herman shall be named by the Board of Directors to complete her term
of office, and (ii) the Board of Directors may be expanded by up to two (2)
additional members in connection with acquisitions that may be completed by
SunAir. Following the expiration of the current term of the Board of Directors
in January, 2004, for the one (1) year period following the current term, two
(2) of the members of the current Board of Directors shall remain as members of
the Board of Directors and further that for the one (1) year term after such
term (or the second year after the expiration of the current term), one (1) of
the members of the current Board of Directors shall be a member of the Board of
Directors.

          (b)  That the indemnity protections provided by the existing Articles of
Incorporation and bylaws of SunAir shall not be amended to lesson or decrease
indemnity provided by SunAir to its officers and directors.

          (c)  That the cash currently held by SunAir shall be retained and utilized
as needed for operations of SunAir and not used for repayment of any
indebtedness owed by Herman or any other third party.

     2.     Control Share Acquisition Statute. SunAir hereby confirms that it has
taken any and all actions, including without limitation the conditional
approval by the Board of Directors of SunAir, necessary or appropriate in order
to opt out of or otherwise render the Florida Control Share Acquisition
Statute, Fla. Stat.ss.607.0902, inapplicable to the direct or indirect
acquisition by Herman of the shares of SunAir held by the Trust immediately
prior to the consummation of the Acquisition and otherwise cause such
acquisition not to constitute a “control share acquisition” under such statute.

     3.     Mutual Representations and Warranties. Each of SunAir and Herman
represents and warrants to the other party to this Agreement as follows: (i)
there is nothing in any agreement such party has entered into that in any way
will limit its ability to perform all of the obligations undertaken by it under
this Agreement; (ii) such party is not a party to any agreement, understanding
or arrangement, direct or indirect, which conflicts with any provisions

4

 

of this Agreement; and (iii) such party has duly authorized, executed and
delivered this Agreement and (assuming the due authorization, execution and
delivery of this Agreement by the other parties hereto) constitutes a valid and
binding obligation of such party.

     4.     Right to Injunction. In the event any party to this Agreement breaches
any provision contained in this Agreement, each of the parties acknowledge that
a remedy at law for damages will be inadequate and that the parties seeking to
enforce this Agreement will be entitled to an injunction to prevent prospective
or continuing breaches hereof.

     5.     Term. The provisions of this Agreement shall survive until the
three-year anniversary of the effective date of the Acquisition.

     6.     Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Florida.

     7.     Severability. The invalidity of any one or more clauses or sections
contained in this Agreement shall not affect the enforceability of the
remaining portions of this Agreement or any part thereof, all of which are
inserted conditionally on their being valid in law and, in the event that any
one or more of the clause or sections contained in this Agreement shall be
declared invalid, this Agreement shall be construed as if such invalid clauses
or sections had not been inserted.

     8.     Waivers. The waiver by a party hereto of a breach or violation of any
term or provision of this Agreement shall not operate nor be construed as a
waiver of any subsequent breach or violation.

     9.     Entire Agreement. Except for the Confidentiality Agreement dated June
24, 2003, this Agreement represents the entire understanding and agreement
among the parties with respect to the subject matter hereof, and supersedes all
other agreements, negotiations, understandings and representations between such
parties with respect to the subject matter hereof.

     10.     Counterparts. This Agreement may be executed in two or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when two or more counterparts have been signed by each
of the parties and delivered to the other parties, it being understood that all
parties need not sign the same counterparts.

(SIGNATURES FOLLOW ON ATTACHED PAGE)

5

 

     IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the
date first above written.

	 	 	 
	 	 	 
	 	 	 
	 	 	
/s/ Michael Herman
	 	 	

	 	 	
Michael Herman, Individually
	 	 	 
	 	 	 
	 	 	
SunAir Electronics, Inc.
	 	 	 
	 	 	 
	 	 	
By: /s/ Synnott B. Durham
	 	 	

	 	 	
Synnott B. Durham, Chief Financial

Officer and Treasurer

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]